Trial Profile
A Phase 2, Single-arm, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or With Other Aggressive B-Cell Malignancies
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs Lisocabtagene-maraleucel (Primary)
- Indications B-cell lymphoma; CNS cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms PILOT; TRANSCEND-WORLD-001; TRANSCENDWORLD
- Sponsors Celgene Corporation
- 11 Jan 2024 Status changed from active, no longer recruiting to completed.
- 20 Sep 2023 This trial has been completed in Belgium, according to the European Clinical Trials Database record.
- 29 Aug 2023 Planned End Date changed from 9 Dec 2023 to 15 Dec 2023.